Different β -Blockers in STEMI and Primary PCI

• Status: Not yet recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Hospital of Shandong University
• Treatments: Adrenergic beta-Antagonists; Bisoprolol; Metoprolol

Criteria

Inclusion Criteria:

• Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes;

• Age ≥18 years;

• Informed consent from patient or next of kin.

Exclusion Criteria:

• Nonischaemic Cardiomyopathy;

• Cardiac surgery planed in the 6 months;

• Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation);

• Renal or hepatic failure;

• Malignancy, HIV, or central nervous system disorder;

• Cardiopulmonary resuscitation >15 min and compromised level of consciousness;

• Cardiogenic shock;

• Current participation in any research study involving investigational drugs or devices;

• No written consensus;

• Previous myocardial infarction.